Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
|Articles|October 19, 2011
- ONCOLOGY Nurse Edition Vol 25 No 10
- Volume 25
- Issue 10
Suggested Reading for a Geriatric Oncology Nursing Journal Club
Black B, Herr K, Fine P, et al: The relationship between pain, nonpain symptoms, and quality of life measures in older adults with cancer receiving hospice care. Pain Med 12(6):880–889, 2011.
Advertisement
Articles in this issue
almost 15 years ago
News of Notealmost 15 years ago
Integrative Medicine Conference Calendaralmost 15 years ago
The Complexity of Hereditary Cancer Syndromesalmost 15 years ago
Coenzyme Q10almost 15 years ago
Elder Spousal Grief in the Context of Cancer Caregivingalmost 15 years ago
Our 9/11 Cancer Nursing Connectionalmost 15 years ago
October Is National Breast Cancer Awareness Monthalmost 15 years ago
Counseling Women at High Risk of Ovarian or Endometrial CancerAdvertisement
Related to this article
Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.
The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.
Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive non-muscle invasive bladder cancer.
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
3
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
4
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
5